Clinical Advisory Board Paul A. Bunn, Jr., M.D. Howard A. (Skip) Burris III, M.D. E. David Crawford, M.D. Alan B. Glassberg, M.D. Richard M. Goldberg, M.D. Robert F. Ozols, M.D., Ph.D. Eric J. Small, M.D. Everett E. Vokes, M.D. Paul A. Bunn, Jr., M.D. Dr. Bunn is director of the University of Colorado Cancer Center in Aurora, Colo., where he holds the James Dudley Endowed Chair of Cancer research and is professor of medicine at the University of Colorado Health Sciences Center. Dr. Bunn is past president and current executive director of the International Association for the Study of Lung Cancer (IASLC). He also served on the Board of Directors of the American Association of Cancer Institutes (AACI) and the American Society of Clinical Oncology (ASCO). He is a past ASCO president and chairs the ASCO Foundation Board. He is the chair of the Scientific Advisory Board of the Cancer League of Colorado. Dr. Bunn previously served as chairman of the Oncology Drug Advisory Committee of the U.S. Food and Drug Administration. A fellow of the American College of Physicians, Dr. Bunn is a member of ASCO, the IASLC, the American Society of Hematology, the American Association for Cancer Research and the American Federation for Clinical Research, among others. Active in the Southwest Oncology Group, Dr. Bunn serves on the Lung Cancer Committee. He also is associate editor of Lung Cancer, Physician Data Query (PDQ) and Oncology Times and serves on the editorial board of Drug Resistance Updates. His research interest includes novel therapies in non-small cell and small cell lung cancer. Dr. Bunn received his medical degree from Cornell University Medical Center in New York City. He completed his internship and residency in medicine at the University of California, H.C. Moffitt Hospital in San Francisco and his fellowship in medical oncology at the medicine branch of the National Cancer Institute. Howard A. (Skip) Burris, III, M.D. Dr. Burris is chief medical officer and director of drug development at The Sarah Cannon Research Institute in Nashville, where he is also an associate with Tennessee Oncology, PLLC. Dr. Burris' research interests focus on developing investigational agents and evaluating these compounds in Phase I and II clinical trials. He has published papers on taxanes and topoisomerase I inhibitors. He currently serves on the American Society of Clinical Oncology (ASCO) Board of Directors and is a member of ASCO's Ethics Committee. He received his medical degree from the University of South Alabama and completed his residency and fellowship in hematology/oncology at Brooke Army Medical Center in San Antonio. While there, he served as director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center and was an associate professor at The University of Texas Health Science Center. E. David Crawford, M.D. Dr. Crawford is the distinguished professor of surgery, urology and radiation oncology, and head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver. He also serves as the senior associate director of the University of Colorado Comprehensive Cancer Center in Denver. Dr Crawford, the recipient of nearly 70 research grants, has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or co-authored more than 450 articles published in peer-reviewed journals and has published five textbooks and authored more than 50 book chapters. He is an editorial reviewer or consultant for many publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer and the Journal of Clinical Oncology. Dr Crawford is a member of the American Urological Association (AUA), for which he was a member of the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Group and chairs the National Prostate Cancer Education Council. He received his medical degree from the University of Cincinnati and completed an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles. Alan B. Glassberg, M.D. Dr. Glassberg previously served as associate director of clinical care and director of general oncology at the University of California, San Francisco (UCSF) Comprehensive Cancer Center. He also served as clinical professor of medicine in the department of hematology/oncology at UCSF, which he joined in 1970. In addition, he served as director of hematology and medical oncology at Mount Zion Medical Center in San Francisco. Dr. Glassberg recently served on the board of directors of the National Comprehensive Cancer Network, a not-for-profit alliance of 20 of the world's leading cancer centers that is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Dr. Glassberg received his M.D. from the Medical University of South Carolina in Charleston. Richard M. Goldberg, M.D. Dr. Goldberg is associate director of clinical research for the University of North Carolina's (UNC) Lineberger Comprehensive Cancer Center and physician-in-chief of the N.C. Cancer Hospital, where he leads the continued development of an integrated, comprehensive system for cancer care, translational research, multidisciplinary patient care and educational opportunities. He is also professor of medicine and chief of the division of hematology and oncology in the UNC School of Medicine's Department of Medicine. Before going to UNC in 2003, he was professor of oncology at the Mayo Clinic in Rochester, Minn., where he chaired the Gastrointestinal Cancer Research Program. Currently, he chairs the Gastrointestinal Cancer Committee for Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute, and is president of the International Society of Gastrointestinal Oncology. Dr. Goldberg is a member of the American Association for Cancer Research, ASCO and the American Joint Commission on Cancer's colorectal task force. He has been an invited reviewer for many leading medical and oncology journals and the editorial boards of the NCI's Physician Data Query program and the Journal of Clinical Oncology and Oncology. His principal research interest is the evaluation of new agents for the treatment of colorectal cancer. He has coauthored more than 160 publications. Dr. Goldberg earned his M.D. from the Upstate Medical Center in Syracuse, N.Y. Robert F. Ozols, M.D., Ph.D. Dr. Ozols is senior vice president of Fox Chase Cancer Center in Philadelphia, where he oversees all of the Center's patient care, clinical research and medical science laboratory research. Internationally recognized for his expertise in ovarian cancer, Dr. Ozols' research focuses on how cancer cells develop resistance to anticancer drugs and on developing new chemotherapy regimens for ovarian cancer. He previously served on the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration. He is a former vice president of the International Gynecologic Cancer Society and served on the Board of Directors of the American Society of Clinical Oncology and the American Association of Cancer Institutes. He is past chair of ASCO's Cancer Research Committee and of the Cancer Communications Committee. He is the author of many scientific publications and has served on the editorial boards of the International Journal of Gynecologic Cancer, International Journal of Oncology, Cancer Research, Cancer Investigation, Journal of Experimental Therapeutics and Oncology and Clinical Cancer Research. He earned his bachelor's degree in chemistry, Ph.D. and M.D. from the University of Rochester. He completed his medical training at Dartmouth-Hitchcock Medical Center and a medical oncology fellowship at the National Cancer Institute. Eric J. Small, M.D. Dr. Small holds joint appointments as a professor in the Department of Urology and Department of Medicine at the University of California, San Francisco (UCSF). He serves as program leader for the Prostate Cancer Program in the Comprehensive Cancer Center at UCSF. In addition to co-directing the Clinical Urologic Oncology Program, he directs the Urologic Oncology Research Office, coordinating more than 30 active protocols for the treatment of urologic malignancies. Dr. Small is chair of the GenitoUrinary Committee of the Cancer and Leukemia Group B (CALGB), a National Cancer Institute Cooperative Oncology Group. He is an active member of numerous professional medical societies, including the American Urological Association and ASCO. Dr. Small is an invited reviewer for many leading oncology and urology journals and has sat on the editorial board of the Journal of Clinical Oncology. His principal research interest is the evaluation of new agents for the treatment of advanced prostate cancer. He has coauthored more than 175 publications. Dr. Small received his bachelor of science degree from Stanford University and attended Case Western Reserve University School of Medicine in Cleveland, where he graduated with honors. He undertook his post-graduate residency training in internal medicine at the Beth Israel Hospital at Harvard University in Boston and completed a fellowship in hematology and oncology at the Cancer Research Institute, UCSF. Everett E. Vokes, M.D. Dr. Vokes is the interim chief executive officer of the University of Chicago Medical Center, interim vice president of medical affairs, interim dean, Biological Sciences Division and Pritzker School of Medicine and the John E. Ultmann Professor of Medicine and Radiation Oncology. Dr. Vokes was educated in West Germany, receiving his medical degree from the University of Bonn Medical School. He served his residency in internal medicine at Ravenswood Hospital Medical Center in Chicago and at the University of Southern California in Los Angeles. He arrived at the University of Chicago as a hematology/oncology fellow in 1983 and was promoted to Professor in 1995. For eleven years he served as chief of the Section of Hematology/Oncology before his appointment as chair of the Department of Medicine in March 2009. Dr. Vokes also serves as deputy director of the University of Chicago's Cancer Research Center. Dr. Vokes has received many awards and has led many professional groups in the field of hematology/oncology. In 2008, he was one of two recipients of the new Translational Research Professorship from the American Society of Clinical Oncology and is a recipient of a Francis L. Lederer Foundation grant for research on the malignancies of the upper aerodigestive tract. Dr. Vokes also has been the principal investigator of the University of Chicago's NCI funded Phase II network since 1994 and has served as chair of the Cancer and Leukemia Group B (CALBG) Respiratory Committee since 2004. Dr. Vokes is an elected member of the prestigious American Society of Clinical Investigation and American Association of Professors (AAP). Dr. Vokes is widely published with over 450 papers and 80 book chapters. He has served on numerous advisory committees and review panels and has served on the editorial boards of several journals, including the Journal of Clinical Oncology, Annals of Oncology, Clinical Lung Cancer, and Investigational New Drugs.